Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma

Pediatric Blood and Cancer

Volumn 60, Issue 10, 2013, Pages 1621-1625

  Raciborska, Anna ^a   Bilska, Katarzyna ^a   Drabko, Katarzyna ^b   Chaber, Radoslaw ^c   Pogorzala, Monika ^d   Wyrobek, Elzbieta ^e   Polczyńska, Katarzyna ^f   Rogowska, Elzbieta ^a   Rodriguez Galindo, Carlos ^g   Wozniak, Wojciech ^a  

^a INSTITUTE OF MOTHER AND CHILD   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Irinotecan; Refractory Ewing sarcoma; Temozolomide

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; TEMOZOLOMIDE; TENIPOSIDE; TROFOSFAMIDE; VINCRISTINE;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG RESPONSE; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME;

IRINOTECAN; REFRACTORY EWING SARCOMA; TEMOZOLOMIDE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SARCOMA, EWING; SURVIVAL RATE; TIME FACTORS; VINCRISTINE;

EID: 84881498429     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24621     Document Type: Article

References (32)

1. Rodriguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies. Cancer 2007; 110:375-384.
2. Paulussen M, Craft AW, Lewis I, et al. Results of the EICESS-92 study: Two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26:4385-4393.
3. Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: Results of the Euro-EWING 99 trial. J Clin Oncol 2010; 28:3284-3291.
4. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors. Cancer 2002; 94:561-569.
5. Shankar AG, Ashley S, Craft AW, et al. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003; 40:141-147.
6. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51:334-338.
7. Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549-553.
8. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48:132-139.
9. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53:1029-1034.
10. De Sio L, Milano GM, Castellano A, et al. Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 2006; 47:30-36.
11. Wagner L. Camptothecin-based regiments for treatment of Ewing sarcoma: Past studies and future directions. Sarcoma 2011; 2011:957957.
12. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999; 17:1815-1824.
13. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000; 6:4110-4118.
14. Mascarenhas L, Lyden ER, Breitfeld PB, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of Rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 2010; 28:4658-4663.
15. Jurgens C, Weston C, Lewis I, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47:22-29.
16. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of Irinotecan alone or in combination with Vincristine for the treatment of metastatic Rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007; 25:362-369.
17. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005; 23:4354-4362.
18. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47:795-800.
19. Al-Faris N, Al Harbi T, Goia C, et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcomas? Pediatr Blood Cancer 2007; 49:190-195.
20. Ferrari S, Brach del Prever A, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009; 52:581-584.
21. Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005; 44:338-347.
22. Whelan JS, McTiernan A, Kakouri E, et al. Carboplatin-based chemotherapy for refracrory and recurrent Ewing's tumors. Pediatr Blood Cancer 2004; 43:237-242.
23. Hawkins DS, Bradfield S, Whitlock JA, et al. Topotecan by 21-Day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2006; 47:790-794.
24. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors : A Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19:3463-3469.
25. Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2008; 50:254-258.
26. Rapkin L, Qayed M, Brill P, et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer 2012; 59:854-858.
27. Mora J, Cruz CO, Parareda A, et al. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol 2009; 31:723-729.
28. Fox E, Shreyaskumar P, Kyle W, et al. Phase II study of sequential Gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: Results of sarcoma alliance for research through collaboration study 003. Oncologist 2012; 17:321.
29. Drabko K, Raciborska A, Bilska K, et al. Consolidation of first-line therapy with BU and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. Bone Marrow Transplant 2012; 47:1530-1534.
30. Juergens H, Daw NC, Geoerger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011; 29:4534-4540.
31. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II Sarcoma alliance for research through collaboration study. J Clin Oncol 2011; 29:4541-4547.
32. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I Consortium study. Pediatr Blood Cancer 2010; 54:538-545.